Dividendos de Acrux

Dividendo controles de criterios 0/6

Acrux no paga actualmente dividendo.

Información clave

Rentabilidad por dividendo

Ratio de pago

Rentabilidad media de la industria	2.2%
Próxima fecha de pago de dividendos	n/a
Fecha ex dividendo	n/a
Dividendo por acción	n/a
Beneficios por acción	-AU$0.0024
Rentabilidad por dividendo prevista a 3 años	n/a

Últimas actualizaciones de dividendos

No hay actualizaciones

Recent updates

Here's Why Shareholders May Want To Be Cautious With Increasing Acrux Limited's (ASX:ACR) CEO Pay Packet

Nov 16

It's Unlikely That Acrux Limited's (ASX:ACR) CEO Will See A Huge Pay Rise This Year

Nov 16

Estabilidad y crecimiento de los pagos

Obteniendo datos sobre dividendos

Dividendo estable: No hay datos suficientes para determinar si los dividendos por acción de ACR han sido estables en el pasado.

Dividendo creciente: Datos insuficientes para determinar si los pagos de dividendos de ACR han aumentado.

Rentabilidad por dividendo vs. Mercado

Rentabilidad por dividendo de Acrux vs. Mercado

¿Cómo se compara la rentabilidad por dividendo de ACR con la del mercado?
Segmento	Rentabilidad por dividendo
Empresa (ACR)	0%
Suelo de mercado 25% (AU)	2.7%
Techo de mercado 25% (AU)	6.4%
Media de la industria (Pharmaceuticals)	2.2%
Previsión de analistas en 3 años (ACR)	n/a

Dividendo destacado: No es posible evaluar la rentabilidad por dividendo de ACR en comparación con el 25% inferior de los pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Alto dividendo: No es posible evaluar la rentabilidad por dividendo de ACR en comparación con el 25% de los principales pagadores de dividendos, ya que la empresa no ha comunicado ningún pago reciente.

Pago de beneficios a los accionistas

Cobertura de los beneficios: ACR no paga un dividendo notable para el mercado Australian.

Pago en efectivo a los accionistas

Cobertura de flujo de caja: No es posible calcular la sostenibilidad de los dividendos, ya que ACR no ha comunicado ningún pago.

Dividendos de Acrux

Dividendo controles de criterios 0/6

Información clave

Últimas actualizaciones de dividendos

Recent updates

First half 2024 earnings released: AU$0.011 loss per share (vs AU$0.011 loss in 1H 2023)

Acrux Limited to Report First Half, 2024 Results on Feb 23, 2024

Acrux Limited, Annual General Meeting, Nov 29, 2023

Full year 2023 earnings released: AU$0.003 loss per share (vs AU$0.035 loss in FY 2022)

New minor risk - Financial data availability

New minor risk - Share price stability

Independent Non-Executive Director recently bought AU$92k worth of stock

First half 2023 earnings released: AU$0.011 loss per share (vs AU$0.019 loss in 1H 2022)

Acrux and Padagis Announce the Launch of Prilocaine and Lidocaine Cream in the United States

Here's Why Shareholders May Want To Be Cautious With Increasing Acrux Limited's (ASX:ACR) CEO Pay Packet

Acrux Limited, Annual General Meeting, Nov 23, 2022

Full year 2022 earnings released: AU$0.035 loss per share (vs AU$0.057 loss in FY 2021)

Acrux's Sixth Generic Dossier Accepted by FDA for Review

Less than half of directors are independent

Non-Executive Director recently bought AU$89k worth of stock

It's Unlikely That Acrux Limited's (ASX:ACR) CEO Will See A Huge Pay Rise This Year

We Think Acrux (ASX:ACR) Needs To Drive Business Growth Carefully

Acrux Limited Announces Fifth Generic Dossier Accepted by FDA for Review

Acrux Limited Launches Testosterone Topical Solution USP, 30mg Per Actuation

Full year 2021 earnings released: AU$0.057 loss per share (vs AU$0.056 loss in FY 2020)

CFO & Company Secretary Deborah Ambrosini has left the company

Acrux Receives Approval from the FDA for Its Generic Version of Jublia

Non Executive Director Norman Gray has left the company

Acrux Confirms Patent Challenge

Here's Why We're Watching Acrux's (ASX:ACR) Cash Burn Situation

Is Acrux (ASX:ACR) In A Good Position To Invest In Growth?

Acrux Limited Announces the US Food and Drug Administration Approves its Generic Product Based on Perrigo's Testosterone Topical Solution, 30mg/1.5mL

New 90-day high: AU$0.21

Acrux Limited announced that it expects to receive AUD 7.815143 million in funding from Bioscience Managers Pty Ltd and other investors

Here's What We Think About Acrux's (ASX:ACR) CEO Pay

Acrux Limited Signs Licensing Agreement with Dash Pharmaceuticals

Full year earnings released - AU$0.057 loss per share

Estabilidad y crecimiento de los pagos

Rentabilidad por dividendo vs. Mercado

Pago de beneficios a los accionistas

Pago en efectivo a los accionistas

Discover strong dividend paying companies